Although type 2 diabetes--specific pharmacotherapy is well studied and efficacious, it is associated with poor long-term adherence, potential side effects, and high costs. Therefore, identification of alternative therapeutic options that can be applied at the public health level are needed to decrease diabetes-related burdens and costs.

Suboptimal vitamin D status has emerged as a potential contributor to the pathophysiology of type 2 diabetes, with several lines of evidence supporting a role for vitamin D in pancreatic *β*-cell function and insulin sensitivity \[[@B1], [@B2]\]. Several trials have examined the effect of vitamin D supplementation (with or without calcium) on glycemia and insulin sensitivity in patients with type 2 diabetes; results are summarized in recent meta-analyses \[[@B3]\]. George *et al.* \[[@B3]\] performed a meta-analysis of trials among patients with type 2 diabetes or impaired glucose tolerance and noted a significant reduction of fasting glucose (\~6 mg/dL) and improvement in insulin sensitivity in patients given vitamin D supplementation vs placebo. A meta-analysis by Seida *et al.* \[[@B4]\] reported nonstatistically significant improvements in hemoglobin A1c (HbA1c), fasting glucose, and insulin sensitivity. In 2017, three meta-analyses of trials using vitamin D in patients with type 2 diabetes reported concordant results \[[@B5]\]. In the first study, Wu *et al.* \[[@B5]\] found that vitamin D supplementation reduced HbA1c significantly (24 trials) and reduced fasting glucose nonsignificantly (18 trials). Among patients with baseline 25-hydroxyvitamin D \[25(OH)D\] \<20 ng/mL, reductions in HbA1c and fasting glucose were significant. In the second study, Mirhosseini *et al.* \[[@B6]\] reported statistically significant reductions in HbA1c, fasting glucose, and insulin resistance (assessed by Homeostatic Model Assessment of Insulin Resistance) after vitamin D supplementation compared with placebo in an analysis of 24 trials. Finally, Krul-Poel *et al.* \[[@B7]\] reported no statistically significant improvements in HbA1c and fasting glucose favoring vitamin D. Although the summary results from these meta-analyses support a beneficial effect of vitamin D supplementation on glycemia and insulin sensitivity in patients with type 2 diabetes, the available trials were short term and of varied quality, had small sample sizes, and had a varied mode of vitamin D administration; therefore, definitive conclusions cannot be drawn from individual trials and meta-analyses. Only two small, short-term trials (n = 24 patients, 16 weeks \[[@B8]\]; n = 37 patients, 12 weeks \[[@B9]\]) have been conducted in the United States; therefore, the effect of vitamin D supplementation among American adults with type 2 diabetes is not known.

The aim of this study was to evaluate the effectiveness of oral daily vitamin D supplementation on pancreatic *β*-cell function and glycemia and its safety in US adults with well-controlled type 2 diabetes.

1. Materials and Methods {#s10}
========================

A. Overview of Study Design {#s11}
---------------------------

The Vitamin D for Established Type 2 Diabetes Mellitus (DDM2) study was a two-site (Tufts Medical Center, Boston, MA, and Veterans Affairs Medical Center, Cincinnati, OH), parallel-group, double-blind, randomized, placebo-controlled trial conducted between March 2013 (first patient enrolled) and July 2015 (final data collection) to examine the effect of vitamin D supplementation on pancreatic *β*-cell function (primary outcome) and HbA1c (secondary outcome) in US adults with stable, well-controlled type 2 diabetes. The study was approved by the Institutional Review Board of Tufts Medical Center and University of Cincinnati, and all participants provided written informed consent.

B. Setting and Participants {#s12}
---------------------------

Patients were recruited *via* a search of electronic medical records. Eligible patients were 25 to 75 years of age, had a body mass index (BMI) of 23 to 42 kg/m^2^, had type 2 diabetes defined by being treated with a stable dose of metformin monotherapy or meeting laboratory criteria for diabetes at screening \[fasting glucose ≥126 mg/dL, HbA1c ≥6.5%, or glucose ≥200 mg/dL 2 hours after a 75-g oral glucose load (2hPG)\], and had stable diabetes defined by HbA1c ≤7.5% without any anticipated change in diabetes therapy in the next 24 weeks. Exclusion criteria included use of any diabetes pharmacotherapy other than metformin; history of type 1 diabetes or secondary diabetes (*e.g.*, cystic fibrosis); and recent history of hyperparathyroidism, nephrolithiasis, or hypercalcemia. Vitamin D status, defined by blood 25(OH)D concentration at baseline, was not an inclusion criterion because (1) the definition of "optimal" vitamin D status is controversial, and no consensus exists on an optimal blood 25(OH)D level \[[@B10]\]; (2) 25(OH)D concentration varies by season and race \[[@B10]\]; (3) the study was designed to be as inclusive as possible to ensure that results are generalizable to clinical practice; and (4) screening with blood 25(OH)D would have been cumbersome and expensive.

C. Intervention {#s13}
---------------

After baseline measurements, patients were randomly assigned in a 1:1 ratio to receive either one pill of 4000 IU of vitamin D~3~ (cholecalciferol) or placebo daily for 48 weeks. The dose of 4000 IU daily was selected to provide an appropriate balance of safety (consistent with the upper safe limit suggested by the Institute of Medicine \[[@B10]\]) and efficacy in terms of obtaining a substantial difference in blood 25(OH)D concentration between the active and placebo groups. Randomization was computer generated in random blocks of four or eight and stratified by BMI (\<30 or ≥30 kg/m^2^), race \[white or non-white (e.g., American Indian, Asian, Pacific Islander, Black)\], and diabetes therapy (lifestyle only or lifestyle plus metformin). Patients and investigators were blinded to treatment assignment. For the first 24 weeks, patients' physicians were asked not to change diabetes therapy whenever possible. For the last 24 weeks, changes in pharmacotherapy were allowed consistent with good clinical practice. Vitamin D~3~ and matching placebos were manufactured by Tishcon Corporation (Salisbury, MD). Quality control analyses were performed on each lot shipped from the manufacturing plant to ensure that vitamin D pills contained the stated amount. The first lot contained 4400 IU and the second lot 4384 IU per pill; both amounts are within specifications (3600 to 4800 IU). Placebo pills did not contain vitamin D. Adherence was assessed by pill count as the percentage of pills taken in relation to the number that should have been taken. A food frequency questionnaire was completed at baseline \[[@B15], [@B16]\].

D. Follow-up and Measurements {#s14}
-----------------------------

Patients were seen at 16, 24, 36, and 48 weeks, and blood was obtained after an 8-hour overnight fast. Patients held their study pill (vitamin D or placebo), metformin, and any other medications until after testing was completed. At baseline and week 24, a 75-g oral glucose tolerance test (OGTT) was done, and blood for glucose, insulin, and C-peptide was collected at 0, 15, 30, 60, 90, 120, 150, and 180 minutes after ingestion of the glucose load. Screening and safety laboratories and HbA1c were analyzed on the same day at each site's clinical laboratory. Blood for other outcomes was processed and stored at −80°C until analyses, which were done by the central laboratory (Tufts Medical Center or Duke University) in pairs (before/after intervention) in the same analytical run to reduce systematic error and interassay variability. HbA1c was measured at baseline and at week 16, 24, 36, and 48 using high-performance liquid chromatography (Tosoh G8; Tosoh Bioscience, South San Francisco, CA; coefficient of variation 0.78 to 1.89). Total 25(OH)D was measured by liquid chromatography-mass spectrometry, which was certified through the National Institute of Standards and Technology vitamin D quality assurance program. Glucose was measured on a Beckman DxC600 clinical analyzer (Beckman, Brea, CA; coefficient of variation \<1%). Insulin and C-peptide were measured by enzyme-linked immunosorbent assay (Alpco, Salem, NH; coefficient of variation \<5%).

E. Outcomes {#s15}
-----------

The primary endpoint was change from baseline to 24 weeks in insulin secretion rate (ISR), estimated from glucose and C-peptide from the OGTT by deconvolution analysis using a two-compartment model with standard parameters for C-peptide kinetics \[[@B17], [@B18]\]. Additional indices included change in *β*-cell function by the Insulin Secretion-Sensitivity Index-2 (ISSI-2) \[[@B19]\], which is equivalent to the disposition index for *β*-cell function, and change in insulin sensitivity by the Matsuda insulin sensitivity index (ISI-M), calculated as \[10,000/sqrt (G0 × I0 × G120 × I120)\], where 10,000 is a constant, G0 and G120 represent the plasma glucose concentrations at time 0 and 120 minutes, I0 and I120 are the plasma insulin concentrations at time 0 and 120 minutes, and sqrt is the mathematical function to calculate the square root \[[@B20]\]. ISSI-2 is defined as the incremental area under the curve (*i.e.*, above baseline) for insulin (AUC~ins~) to the incremental area under the curve for glucose (AUC~glu~) multiplied by the ISI-M \[(AUC~ins~/AUC~glu~)ISI-M\] \[[@B21], [@B22]\]. Other prespecified analyses included change in HbA1c, change in glycemia, variability of response to vitamin D supplementation in subgroups defined by the following baseline characteristics: race (white vs non-white), 25(OH)D concentration (\<20 vs ≥20 ng/mL), diabetes therapy (lifestyle only vs lifestyle plus metformin), effect of vitamin D supplementation on plasma 25(OH)D concentration, and safety and tolerability of vitamin D supplementation. Change in glycemia was a dichotomous ("decrease" or "no change") composite outcome to assess concomitant reductions in the related outcomes of HbA1c and diabetes medication use. Patients who had a "decrease" in the diabetes medications or a reduction of ≥0.4 HbA1c units from baseline without increasing medications were defined as having achieved the composite outcome.

F. Statistical Methods {#s16}
----------------------

Analyses were by intention-to-treat, defined as all participants in their randomly assigned treatment group and including all available measurements irrespective of adherence to assigned treatment. The difference between treatment groups in the primary endpoint (*i.e.*, change from baseline to 24 weeks in ISR) was assessed using linear regression. Analyses adjusted for the stratification variables \[(BMI \<30 or ≥30 kg/m^2^), race (white vs non-white), and diabetes therapy (lifestyle only vs lifestyle plus metformin)\] and baseline value of the outcome variable.Between-group differences for the change in HbA1c were determined using a mixed model approach to account for within-participant correlation across the four time points. A linear interaction term between treatment assignment and time from baseline visit, included as a covariate, was used to assess if the change trajectories in HbA1c levels differed significantly between randomization groups. Secondary analyses explored potential nonlinear changes over the 48 weeks of follow-up. The likelihood of achieving the "glycemia" composite outcome was assessed with *χ*^2^ tests. In sample size calculations for the primary endpoint at 6 months, we assumed a between-group difference at week 24 in "change in total ISR" of 65 pmol/min/m^2^, a standard deviation of the difference in ISR of 104 (which represents a difference of \~30% improvement) \[[@B21]\], and a 90% participant retention rate. The required sample size assuming a two-sided 5% type 1 error rate and 90% power was 124 participants. Statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).

2. Results {#s17}
==========

A. Participants and Baseline Characteristics {#s18}
--------------------------------------------

From February 2013 through July 2014, a total of 399 patients were prescreened by telephone, and 198 completed in-person screening ([Fig. 1](#F1){ref-type="fig"}). Of these, 127 met eligibility criteria and were randomly assigned to vitamin D~3~ (n = 66) or placebo (n = 61). Patient characteristics at baseline were balanced between the two groups, especially for the key factors BMI, race, and diabetes therapy ([Table 1](#T1){ref-type="table"}). Consistent with a population with type 2 diabetes, the mean age was 60.2 years, and mean BMI was 30.9 kg/m^2^. Diabetes was well controlled (mean HbA1c, 6.6%), and most patients (78%) were on metformin. Thirty percent were women, and 62% were white. Mean plasma 25(OH)D concentration was 26.6 ng/mL. Twenty-six percent of patients (n = 33) had a 25(OH)D concentration \<20 ng/mL. Mean self-reported vitamin D intake was 399 IU/d.

![Flow of participants. All four patients who withdrew from the study did so for personal reasons. Three patients returned for the week 24 visit but did not complete the OGTT for technical reasons. These patients are not included in the analysis of OGTT-based indices but are included in the HbA1c analysis.](js.2018-00015f1){#F1}

###### 

Baseline Characteristics

  Characteristics                                                               Total (n = 127)   Vitamin D (n = 66)   Placebo (n = 61)
  ----------------------------------------------------------------------------- ----------------- -------------------- ------------------
  Demographics                                                                                                         
   Age, y                                                                       60.2 (8.4)        60.1 (8.4)           60.3 (8.5)
   Female, n (%)                                                                38 (29.9)         17 (25.8)            21 (34.4)
   Race, n (%)[*^a^*](#t1n1){ref-type="table-fn"}                                                                      
    White                                                                       79 (62.2)         41 (62.1)            38 (62.3)
    Black or African-American                                                   38 (29.9)         17 (25.8)            21 (34.4)
    Asian                                                                       6 (4.7)           4 (6.1)              2 (3.3)
    Other                                                                       4 (3.1)           4 (6.1)              0 (0)
   Hispanic or Latino ethnicity, n (%)[*^a^*](#t1n1){ref-type="table-fn"}       3 (2.4)           2 (3.0)              1 (1.6)
   Season at study entry, n (%)                                                                                        
    January--March                                                              33 (26.0)         15 (22.7)            18 (29.5)
    April--June                                                                 45 (35.4)         27 (40.9)            18 (29.5)
    July--September                                                             32 (25.2)         17 (25.8)            15 (24.6)
    October--December                                                           17 (13.4)         7 (10.6)             10 (16.4)
   Self-reported vitamin D intake, units/d[*^b^*](#t1n2){ref-type="table-fn"}   399 (343)         407 (381)            391 (301)
   Self-reported calcium intake, mg/d[*^b^*](#t1n2){ref-type="table-fn"}        931 (513)         1006 (597)           852 (394)
   Smoking status, n (%)                                                                                               
    Never smoked                                                                48 (37.8)         22 (33.3)            26 (42.6)
    Currently smoking                                                           14 (11.0)         8 (12.1)             6 (9.8)
    Formerly smoked                                                             64 (50.4)         35 (53.0)            29 (47.5)
    Prefer not to answer                                                        1 (0.8)           1 (1.5)              0 (0)
  Clinical characteristics                                                                                             
   Weight, kg                                                                   92.0 (15.5)       91.2 (15.9)          92.9 (15.1)
   BMI, kg/m^2^                                                                 30.9 (3.8)        30.7 (3.9)           31.2 (3.8)
   Metformin use, n (%)                                                         99 (78.0)         51 (77.3)            48 (78.7)
  Laboratory                                                                                                           
   Serum calcium, mg/dL                                                         9.5 (0.4)         9.5 (0.4)            9.4 (0.3)
   Vitamin D status                                                                                                    
    Plasma 25(OH)D, ng/mL                                                       26.6 (11.1)       25.8 (10.3)          27.5 (12.0)
    Plasma 25(OH)D \<20 ng/mL, n (%)                                            33 (26.0)         19 (28.8)            14 (23.0)
    Plasma 25(OH)D \<30 ng/mL, n (%)                                            80 (63.0)         42 (63.6)            38 (62.3)
   HbA1c, %                                                                     6.6 (0.5)         6.6 (0.6)            6.5 (0.5)

Values are means (standard deviation) unless otherwise specified. Percentages may not total 100 because of rounding. To convert 25(OH)D from ng/mL to mmol/L, multiply by 2.456; to convert vitamin D intake from international units to μg, divide by 40.

Race and ethnicities were self-reported and followed National Institutes of Health guidelines. Participants could check multiple categories. Asian includes "Chinese" (n = 3) and "Other Asian" (n = 3). Other includes "Native Hawaiian or Other Pacific Islander" (n = 1) and "Other" (n = 3).

Data are derived from the food frequency questionnaire.

B. Retention and Adherence to Study Pills {#s19}
-----------------------------------------

Of the 127 patients, 94% (n = 120) and 90% (n = 114) returned for the week 24 and week 48 visits, respectively ([Fig. 1](#F1){ref-type="fig"}). Mean adherence to study pills was 94% for vitamin D~3~ and 93% for placebo. At week 24, the plasma 25(OH)D concentration was 47.1 ng/mL (an increase of 20.5 ng/mL from baseline) in the vitamin D~3~ group vs 25.5 ng/mL (a decrease of 1.6 ng/mL from baseline) in the placebo group (*P* \< 0.001 for vitamin D~3~ vs placebo) ([Fig. 2](#F2){ref-type="fig"}). Plasma 25(OH)D concentration remained constant at week 48.

![Plasma 25(OH)D concentration during the study. \**P* \< 0.001 for vitamin D vs placebo.](js.2018-00015f2){#F2}

C. Change in OGTT-Based Indices at Week 24 {#s20}
------------------------------------------

After supplementation with vitamin D, there was no difference in the change from baseline to 24 weeks in fasting or total ISR between the two groups ([Table 2](#T2){ref-type="table"}). There was also no difference in the ISI-M between vitamin D and placebo. The ISSI-2 increased in vitamin D vs placebo-treated patients, but the difference was not statistically significant (0.149 for vitamin D vs 0.023 for placebo; *P* = 0.118). Changes in AUC~glu~ and AUC~ins~ were not different between the two groups. There was also no difference in glycemia and C-peptide between vitamin D and placebo ([Supplemental Fig. 1](#sup1){ref-type="supplementary-material"}).

###### 

Effects of Vitamin D Supplementation on OGTT Indices at 24 Weeks

                                     Change from Baseline to 24 weeks   *P* Value         
  ---------------------------- ----- ---------------------------------- ----------------- -------
  ISR fasting, pmol/min/m^2^   120   −0.700 ± 5.237                     −1.684 ± 5.326    0.896
  ISR total, pmol/min/m^2^     118   622.88 ± 1786.0                    778.41 ± 1816.6   0.952
  ISI-Matsuda                  118   0.111 ± 0.264                      −0.108 ± 0.269    0.562
  ISSI-2                       118   0.149 ± 0.056                      0.023 ± 0.057     0.118
  AUC~glu~                     119   3.357 ± 883.27                     −130.7 ± 890.75   0.915
  AUC~ins~                     119   −772.5 ± 424.61                    −890.3 ± 428.19   0.845

Values are mean ± standard error of the mean after adjustment for stratified variables \[(BMI \<30 or ≥30 kg/m^2^), race (white vs non-white), diabetes therapy (metformin or lifestyle)\], and baseline value of the outcome variable.

After excluding four participants who changed diabetes medications during the first 24 weeks, results did not change (not shown). In subgroup analyses by diabetes therapy (lifestyle only vs lifestyle plus metformin), 25(OH)D concentration at baseline (\<20 vs ≥20 ng/mL), or race (white vs nonwhite), there was no significant effect of vitamin D supplementation on OGTT-based indices compared with placebo (results not shown).

D. Change in Glycemia at Week 24 and Week 48 {#s21}
--------------------------------------------

During follow-up, HbA1c concentration increased in both the vitamin D and placebo groups without any difference between the two treatment groups ([Table 3](#T3){ref-type="table"}). More patients treated with vitamin D experienced improvement in the "glycemia" composite outcome at 24 weeks (14.8% vs 10.2% for vitamin D vs placebo, respectively) and 48 weeks (10.2% vs 5.4%), but these differences were not statistically significant.

###### 

Effect of Vitamin D Supplementation on Glycemia

                                                                                          N Used in Analyses   Change From Baseline   *P* Value      
  --------------------------------------------------------------------------------------- -------------------- ---------------------- -------------- ------------------------------------------
  HbA1c, %                                                                                                                                           0.882[*^a^*](#t3n1){ref-type="table-fn"}
   Wk 16                                                                                  117                  0.1 ± 0.06             0.1 ± 0.06     0.749[*^b^*](#t3n2){ref-type="table-fn"}
   Wk 24                                                                                  120                  0.1 ± 0.06             0.1 ± 0.06     0.699[*^b^*](#t3n2){ref-type="table-fn"}
   Wk 36                                                                                  114                  0.2 ± 0.07             0.1 ± 0.07     0.581[*^b^*](#t3n2){ref-type="table-fn"}
   Wk 48                                                                                  114                  0.2 ± 0.06             0.2 ± 0.07     0.866[*^b^*](#t3n2){ref-type="table-fn"}
  Change in glycemia from baseline to wk 24, % (n/N)[*^c^*](#t3n3){ref-type="table-fn"}   120                                                        
   Decreased                                                                                                   14.8 (9/61)            10.2 (6/59)    0.448
   Increased or no change                                                                                      85.2 (52/61)           89.8 (53/59)   
  Change in glycemia from baseline to wk 48, % (n/N)                                      114                                                        
   Decreased                                                                                                   10.2 (6/59)            5.4 (3/55)     0.351
   Increased or no change                                                                                      89.8 (53/59)           94.6 (52/55)   

Values are mean ± standard error of the mean after adjustment for stratified variables \[(BMI \<30 or ≥30 kg/m^2^), race (white vs non-white), diabetes therapy (metformin or lifestyle)\] and baseline value of the outcome variable.

*P* value for the overall difference over time from linear mixed model.

*P* values for the difference at each time point.

"Change in glycemia" is a composite outcome prespecified as follows: "decreased," if the intensity of diabetes medication was lowered or HbA1c decreased by ≥0.4% during the follow-up period; "Increased or no change."

After excluding four participants who changed diabetes medications by week 24 and 11 participants who changed diabetes medications at any point during the trial, HbA1c results did not change (results not shown). Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (−0.1 vs 0.3%, respectively; *P* = 0.034) at week 24 ([Table 4](#T4){ref-type="table"}); however, there was no difference at the other time points. More patients treated with vitamin D also experienced improvement in the "glycemia" composite outcome (28.6% vs 0% for vitamin D vs placebo, respectively); however, the differences were not statistically significant. In subgroup analyses by 25(OH)D concentration at baseline (\<20 vs ≥20 ng/mL) or race (white vs non-white), there was no significant effect of vitamin D supplementation on change in HbA1c compared with placebo (results not shown).

###### 

Effect of Vitamin D Supplementation on Glycemia Among Patients Treated With Lifestyle Only (*i.e.*, Not on Metformin)

                                                                                               Change From Baseline   *P* Value     
  --------------------------------------------------------------------------------------- ---- ---------------------- ------------- ------------------------------------------
  Hba1c, %                                                                                                                          0.515[*^a^*](#t4n1){ref-type="table-fn"}
   Wk 16                                                                                  27   0.1 ± 0.14             0.1 ± 0.14    0.929[*^b^*](#t4n2){ref-type="table-fn"}
   Wk 24                                                                                  27   −0.1 ± 0.12            0.3 ± 0.12    0.034[*^b^*](#t4n2){ref-type="table-fn"}
   Wk 36                                                                                  27   −0.0 ± 0.13            0.1 ± 0.13    0.450[*^b^*](#t4n2){ref-type="table-fn"}
   Wk 48                                                                                  27   0.0 ± 0.12             0.0 ± 0.12    0.954[*^b^*](#t4n2){ref-type="table-fn"}
  Change in glycemia from baseline to wk 24, % (n/N)[^*c*^](#t4n3){ref-type="table-fn"}   27                                        0.098
   Decrease                                                                                    28.6 (4/14)            0(0/13)       
   Increase or no change                                                                       71.4 (10/14)           100 (13/13)   
  Change in glycemia from baseline to wk 48, % (n/N)                                      27                                        0.222
   Decrease                                                                                    21.4 (3/14)            0 (0/13)      
   Increase or no change                                                                       78.6 (11/14)           100 (13/13)   

Values are mean ± standard error of the mean after adjustment for stratified variables \[BMI \<30 or ≥30 kg/m^2^, race (white vs non-white), diabetes therapy (metformin or lifestyle)\], and baseline value of the outcome variable.

*P* value for the overall difference over time from linear mixed model.

*P* values for the difference at each time point.

"Change in glycemia" is a composite outcome prespecified as follows: "decreased," if the intensity of diabetes medication was lowered or HbA1c declined by ≥0.4% during the follow-up period; "Increased or no change."

E. Safety {#s22}
---------

The supplements were well tolerated. Two patients discontinued study pills, one due to an adverse event (nephrolithiasis, found incidentally on imaging) and one due to personal choice. Both patients returned for their follow-up visits. There were no cases of hypercalcemia (defined as higher than the upper limit of the normal for the local laboratory). Adverse event rates were similar in the two groups \[0.62 adverse events per patient-year (35 adverse events during 55.9 patient-years of follow-up) in vitamin D vs 0.85 adverse events per patient-year (45 adverse events during 52.6 patient-years of follow-up)\] in placebo.

3. Discussion {#s23}
=============

In this double-blind, placebo-controlled, randomized clinical trial, the effect of oral daily vitamin D~3~ supplementation was investigated in patients with well-controlled type 2 diabetes not selected for vitamin D deficiency. Despite a substantial increase in plasma 25(OH)D concentration, there were no differences in OGTT-based insulin secretion or insulin sensitivity indices after 24 weeks of vitamin D supplementation compared with placebo. We did not find a significant effect of vitamin D supplementation on HbA1c after 48 weeks. In a subgroup of patients treated with lifestyle only, there was a reduction of the HbA1c in the vitamin D group compared with placebo at week 24, which was not seen at other time points.

A. Studies (Observational or Trials) With Similar OGTT Indices {#s24}
--------------------------------------------------------------

Observational studies support an association between blood 25(OH)D concentration and OGTT-based indices of *β*-cell function (assessed by ISSI-2) \[[@B24]\] and insulin sensitivity (assessed by Matsuda Index) \[[@B28], [@B29]\]. Although the summary results from meta-analyses of trials in patients with type 2 diabetes suggest small benefits of vitamin D supplementation in glycemia and insulin sensitivity in patients with type 2 diabetes \[[@B5]\], the available trials are short-term and of varied quality, have small sample sizes, and have varied modes of vitamin D administration; therefore, firm conclusions cannot be drawn. In the largest trial to date in 266 patients with type 2 diabetes in Netherlands, there was no difference in HbA1c or insulin resistance by Homeostatic Model Assessment of Insulin Resistance \[[@B30]\]. However, in patients with baseline 25(OH)D \<12 ng/mL, there was a significant reduction in HbA1c with vitamin D supplementation. This trial involved a well-controlled patient population (baseline HbA1c, 6.8%) and gave high intermittent doses of vitamin D (50,000 IU/mo; equivalent to 1600 units/d), which may not be physiologic \[[@B31]\].

Only two trials based in the United States have tested the effect of vitamin D supplementation in patients with type 2 diabetes. Both studies are small and short-term. Soric *et al.* \[[@B9]\] randomized 37 patients with type 2 diabetes (baseline HbA1c, 8.6%) to 2000 IU/d vitamin D~3~ or 500 mg/d vitamin C for 12 weeks and reported a nonstatistically significant change in HbA1c favoring vitamin D (−0.4% vs 0.1%). Patel *et al.* \[[@B8]\] randomized 32 patients with type 2 diabetes (HbA1c, 6.7%) to 1200 or 400 IU/d of vitamin D~3~ and found no change in HbA1c or insulin resistance quantitative insulin sensitivity check index between the two groups in 24 patients with complete data.

B. Why Negative Results {#s25}
-----------------------

There are several possible explanations as to why vitamin D supplementation did not improve glycemic control of insulin secretion in our cohort besides the possibility that vitamin D may not be relevant to glucose metabolism. The baseline 25(OH)D concentration of the cohort was ∼27 ng/mL, which may indicate an adequate vitamin D status for the metabolic outcomes assessed in DDM2, as suggested by a recent meta-analysis that reported a significant reduction in HbA1c and fasting glucose after vitamin D supplementation only among patients with baseline 25(OH)D \<20 ng/mL. Therefore, the study's results might have been different if the patients had lower baseline 25(OH)D concentrations. In subgroup analyses, we found no difference among patients with 25(OH)D \<20 ng/mL at baseline; however, there were too few individuals with these levels (n = 33) to provide adequate statistical power to evaluate this possibility. Likewise, vitamin D may have no detectable effect in persons with well-controlled diabetes. We specifically recruited patients with good glycemic control to minimize possible interference by multiple antidiabetic drugs or the need to change diabetes pharmacotherapy during the study. As a result, the DDM2 cohort had excellent control of diabetes (mean HbA1c, 6.6%), which may have made it difficult to detect an effect of vitamin D. Additionally, most patients (78%) were on metformin, which may have masked a small effect of vitamin D supplementation on outcomes because there was essentially no change in the placebo group at week 24 (HbA1c rose by only 0.1%). In contrast, in the subgroup of patients managed with lifestyle only, there was a reduction in HbA1c at 24 weeks (−0.1 for vitamin D vs 0.3% for placebo). This result was not observed at the other time points and could be due to chance because of multiple comparisons. These results indicate that any effect of vitamin D supplementation is expected to be relatively small and would be most noticeable among patients with early diabetes not requiring pharmacotherapy. Finally, our power calculations may have been too optimistic, and it is possible that a larger sample size and longer follow-up would be needed to observe an effect.

C. Assessment of Safety and Tolerability of 4000 IU/d of Vitamin D~3~ {#s26}
---------------------------------------------------------------------

A potential concern with long-term vitamin D supplementation is the development of hypercalcemia, hypercalciuria, and kidney stones. A recent meta-analysis of trials showed that vitamin D supplementation increased the risk of hypercalcemia and hypercalciuria in a non--dose-related fashion but did not increase risk of nephrolithiasis \[[@B32]\]. The dosage of 4000 IU/d is the upper limit for toxicity by the Institute of Medicine \[[@B10]\]; however, the safety of this daily dosage has not been tested in a long-term trial. Exposure to 4000 IU/d of vitamin D~3~ for 48 weeks was safe in the DDM2 trial: there were no cases of hypercalcemia and only one case of nephrolithiasis, which was detected incidentally. No patient withdrew for safety reasons.

D. Strengths and Limitations {#s27}
----------------------------

Given the multiple factors than can influence glycemia, the DDM2 trial carefully monitored and adjusted for potential confounders between active and placebo groups (*e.g.*, concurrent diabetes medications). The study has additional strengths, including its randomized, double-blind, placebo-controlled study design; the use of a high-dose (4000 IU) daily vitamin D supplementation; a baseline 25(OH)D that is representative of the US adult population \[[@B33]\]; and excellent retention of participants and adherence to study medications. The study also has some limitations. Because one clinical site recruited patients from a Veterans Administration medical center, the cohort had relatively few women (30%). Additionally, selection of a population that is deplete with vitamin D at baseline might be necessary to see an effect of vitamin D supplementation, especially in a well-controlled cohort that progresses slowly.

4. Conclusion {#s28}
=============

Daily administration of 4000 IU vitamin D~3~ compared with placebo did not improve HbA1c or OGTT-based indices of *β*-cell function or insulin secretion in the largest US-based trial among patients with well-controlled, stable type 2 diabetes not selected for vitamin D deficiency. A reduction in HbA1c was observed at week 24 among patients treated with lifestyle only; however, this result could be due to chance.
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25(OH)D

:   25-hydroxyvitamin D

AUC~glu~

:   area under the curve glucose

AUC~ins~

:   area under the curve insulin

BMI

:   body mass index

DDM2

:   Vitamin D for Established Type 2 Diabetes Mellitus

HbA1c

:   hemoglobin A1c

ISI-M

:   Matsuda insulin sensitivity index

ISR

:   insulin secretion rate

ISSI-2

:   Insulin Secretion-Sensitivity Index-2

OGTT

:   oral glucose tolerance test.
